A real-world study to assess virologic outcomes and effects of resistance associated substitutions in a cohort of GT3 infected patients when retreated with SOF/VEL/VOX

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

01 Sep 2021 Results assessing outcomes of 144 patients failed by first-line DAA therapy and retreated with SOF/VEL/VOX, published in the Journal of Viral Hepatitis.
21 Oct 2020 New trial record
29 Aug 2020 Results presented at The International Liver Congress 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com